Astrocyte plasticity revealed by adaptations to severe proteotoxic stress

Cell and Tissue Research

Volumn 352, Issue 3, 2013, Pages 427-443

  Titler, Amanda M ^a   Posimo, Jessica M ^a   Leak, Rehana K ^a  

^a DUQUESNE UNIVERSITY   (United States)

Author keywords

Dual hit; Glia; Hormesis; Neurodegeneration; Preconditioning; Rat (Sprague Dawley); Toxic stress; Two hit

Indexed keywords

ADENOSINE TRIPHOSPHATE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CHAPERONE; GLUTATHIONE; HEAT SHOCK PROTEIN; UBIQUITIN;

ADAPTATION; ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTE; AUTOPHAGY; CELL STRESS; CELL SURVIVAL; CONTROLLED STUDY; LC 50; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN MISFOLDING; PROTEIN STRUCTURE; PROTEOTOXIC STRESS; PROTEOTOXICITY; RAT; STRESS; TOXICITY;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ASTROCYTES; AUTOPHAGY; BLOTTING, WESTERN; BUTHIONINE SULFOXIMINE; CELL NUCLEUS; CELL SURVIVAL; CELLS, CULTURED; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE; IMMUNOHISTOCHEMISTRY; LEUPEPTINS; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 2; NEURONAL PLASTICITY; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; STRESS, PHYSIOLOGICAL;

RATTUS;

EID: 84878574813     PISSN: 0302766X     EISSN: 14320878     Source Type: Journal    
DOI: 10.1007/s00441-013-1571-4     Document Type: Article

References (134)

1. Abete P, Cacciatore F, Testa G, Della-Morte D, Galizia G, Santis D de, Calabrese C, Cioppa A, Ferrara N, Rengo F (2010) Ischemic preconditioning in the aging heart: from bench to bedside. Ageing Res Rev 9:153-162
2. Akiyama H, Schwab C, Kondo H, Mori H, Kametani F, Ikeda K, McGeer PL (1996) Granules in glial cells of patients with Alzheimer's disease are immunopositive for C-terminal sequences of beta-amyloid protein. Neurosci Lett 206:169-172
3. Akiyama H, Mori H, Saido T, Kondo H, Ikeda K, McGeer PL (1999) Occurrence of the diffuse amyloid beta-protein (Abeta) deposits with numerous Abeta-containing glial cells in the cerebral cortex of patients with Alzheimer's disease. Glia 25:324-331
4. Alexandrova A, Petrov L, Georgieva A, Kirkova M, Kukan M (2008) Effects of proteasome inhibitor, MG132, on proteasome activity and oxidative status of rat liver. Cell Biochem Funct 26:392-398
5. Allen NJ, Barres BA (2009) Neuroscience: glia - more than just brain glue. Nature 457:675-677
6. 2 preconditioning modulates phase II enzymes through p38 MAPK and PI3K/Akt activation. Am J Physiol Heart Circ Physiol 300:H2196-H2205
7. Angot E, Steiner JA, Hansen C, Li JY, Brundin P (2010) Are synucleinopathies prion-like disorders? Lancet Neurol 9:1128-1138
8. Aridon P, Geraci F, Turturici G, D'Amelio M, Savettieri G, Sconzo G (2011) Protective role of heat shock proteins in Parkinson's disease. Neurodegener Dis 8:155-168
9. Aztatzi-Santillan E, Nares-Lopez FE, Marquez-Valadez B, Aguilera P, Chanez-Cardenas ME (2010) The protective role of heme oxygenase-1 in cerebral ischemia. Cent Nerv Syst Agents Med Chem 10:310-316
10. Baldeiras I, Santana I, Proenca MT, Garrucho MH, Pascoal R, Rodrigues A, Duro D, Oliveira CR (2008) Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. J Alzheimers Dis 15:117-128
11. Barres BA (2008) The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60:430-440
12. Bayer SA, Altman J (1991) Neocortical development. Raven, New York
13. Beach TG, McGeer EG (1988) Lamina-specific arrangement of astrocytic gliosis and senile plaques in Alzheimer's disease visual cortex. Brain Res 463:357-361
14. Beal MF (2002) Oxidatively modified proteins in aging and disease. Free Radic Biol Med 32:797-803
15. Boger HA, Granholm AC, McGinty JF, Middaugh LD (2010) A dual-hit animal model for age-related Parkinsonism. Prog Neurobiol 90:217-229
16. Braak H, Sastre M, Del Tredici K (2007) Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol 114:231-241
17. Breusing N, Grune T (2008) Regulation of proteasome-mediated protein degradation during oxidative stress and aging. Biol Chem 389:203-209
18. Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, Xing Y, Lubischer JL, Krieg PA, Krupenko SA, Thompson WJ, Barres BA (2008) A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 28:264-278
19. Calabrese EJ (2008) Astrocytes: adaptive responses to low doses of neurotoxins. Crit Rev Toxicol 38:463-471
20. Calabrese EJ (2010) Hormesis is central to toxicology, pharmacology and risk assessment. Hum Exp Toxicol 29:249-261
21. Calabrese V, Sultana R, Scapagnini G, Guagliano E, Sapienza M, Bella R, Kanski J, Pennisi G, Mancuso C, Stella AM, Butterfield DA (2006) Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal 8:1975-1986
22. Carvey PM, Punati A, Newman MB (2006) Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant 15:239-250
23. Casarejos MJ, Solano RM, Rodriguez-Navarro JA, Gomez A, Perucho J, Castano JG, Garcia de Yebenes J, Mena MA (2009) Parkin deficiency increases the resistance of midbrain neurons and glia to mild proteasome inhibition: the role of autophagy and glutathione homeostasis. J Neurochem 110:1523-1537
24. Chen J, Simon R (1997) Ischemic tolerance in the brain. Neurology 48:306-311
25. Chu PW, Beart PM, Jones NM (2010) Preconditioning protects against oxidative injury involving hypoxia-inducible factor-1 and vascular endothelial growth factor in cultured astrocytes. Eur J Pharmacol 633:24-32
26. Cooper AJ, Kristal BS (1997) Multiple roles of glutathione in the central nervous system. Biol Chem 378:793-802
27. Cory-Slechta DA, Thiruchelvam M, Barlow BK, Richfield EK (2005) Developmental pesticide models of the Parkinson disease phenotype. Environ Health Perspect 113:1263-1270
28. Delacourte A (1990) General and dramatic glial reaction in Alzheimer brains. Neurology 40:33-37
29. Dickson DW (2009) Neuropathology of non-Alzheimer degenerative disorders. Int J Clin Exp Pathol 3:1-23
30. Dirnagl U, Simon RP, Hallenbeck JM (2003) Ischemic tolerance and endogenous neuroprotection. Trends Neurosci 26:248-254
31. Dringen R (2000) Metabolism and functions of glutathione in brain. Prog Neurobiol 62:649-671
32. Dringen R, Gutterer JM, Hirrlinger J (2000) Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur J Biochem 267:4912-4916
33. Du F, Zhu L, Qian ZM, Wu XM, Yung WH, Ke Y (2010) Hyperthermic preconditioning protects astrocytes from ischemia/reperfusion injury by up-regulation of HIF-1 alpha expression and binding activity. Biochim Biophys Acta 1802:1048-1053
34. Du F, Qian ZM, Zhu L, Wu XM, Yung WH, Ke Y (2011) A synergistic role of hyperthermic and pharmacological preconditioning to protect astrocytes against ischemia/reperfusion injury. Neurochem Res 36:312-318
35. Duyckaerts C, Delatour B, Potier MC (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118:5-36
36. Dwyer BE, Nishimura RN, Lu SY (1995) Differential expression of heme oxygenase-1 in cultured cortical neurons and astrocytes determined by the aid of a new heme oxygenase antibody. Response to oxidative stress. Brain Res Mol Brain Res 30:37-47
37. Eng LF, Ghirnikar RS (1994) GFAP and astrogliosis. Brain Pathol 4:229-237
38. Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP - thirty-one years (1969-2000). Neurochem Res 25:1439-1451
39. Finn PF, Mesires NT, Vine M, Dice JF (2005) Effects of small molecules on chaperone-mediated autophagy. Autophagy 1:141-145
40. Fuertes G, Martin De Llano JJ, Villarroya A, Rivett AJ, Knecht E (2003) Changes in the proteolytic activities of proteasomes and lysosomes in human fibroblasts produced by serum withdrawal, amino-acid deprivation and confluent conditions. Biochem J 375:75-86
41. Gandelman M, Peluffo H, Beckman JS, Cassina P, Barbeito L (2010) Extracellular ATP and the P2X7 receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis. J Neuroinflamm 7:33
42. Gao HM, Hong JS (2011) Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. Prog Neurobiol 94:1-19
43. Garcia AD, Doan NB, Imura T, Bush TG, Sofroniew MV (2004) GFAP-expressing progenitors are the principal source of constitutive neurogenesis in adult mouse forebrain. Nat Neurosci 7:1233-1241
44. Gegg ME, Clark JB, Heales SJ (2005) Co-culture of neurones with glutathione deficient astrocytes leads to increased neuronal susceptibility to nitric oxide and increased glutamate-cysteine ligase activity. Brain Res 1036:1-6
45. Ghosh N, Ghosh R, Mandal SC (2011) Antioxidant protection: a promising therapeutic intervention in neurodegenerative disease. Free Radic Res 45:888-905
46. Giordano J, Ives JA, Jonas WB (2008) Hormetic responses in neural systems: consideration, contexts, and caveats. Crit Rev Toxicol 38:623-627
47. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373-428
48. Gong SJ, Chen LY, Zhang M, Gong JX, Ma YX, Zhang JM, Wang YJ, Hu YY, Sun XC, Li WB, Zhang Y (2012) Intermittent hypobaric hypoxia preconditioning induced brain ischemic tolerance by up-regulating glial glutamate transporter-1 in rats. Neurochem Res 37:527-537
49. Grochot-Przeczek A, Dulak J, Jozkowicz A (2012) Haem oxygenase-1: non-canonical roles in physiology and pathology. Clin Sci (Lond) 122:93-103
50. Gundersen V (2010) Protein aggregation in Parkinson's disease. Acta Neurol Scand Suppl 190:82-87
51. Han YH, Park WH (2010) MG132, a proteasome inhibitor decreased the growth of Calu-6 lung cancer cells via apoptosis and GSH depletion. Toxicol in Vitro 24:1237-1242
52. Han YH, Moon HJ, You BR, Yang YM, Kim SZ, Kim SH, Park WH (2010a) MG132, a proteasome inhibitor, induced death of calf pulmonary artery endothelial cells via caspase-dependent apoptosis and GSH depletion. Anticancer Res 30:879-885
53. Han YH, Yang YM, Kim SZ, Park WH (2010b) Attenuation of MG132-induced HeLa cell death by N-acetyl cysteine via reducing reactive oxygen species and preventing glutathione depletion. Anticancer Res 30:2107-2112
54. Heinsen H, Strik M, Bauer M, Luther K, Ulmar G, Gangnus D, Jungkunz G, Eisenmenger W, Gotz M (1994) Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol 88:320-333
55. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC (2004) Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62:925-931
56. Ischiropoulos H, Beckman JS (2003) Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest 111:163-169
57. Iwata A, Riley BE, Johnston JA, Kopito RR (2005) HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 280:40282-40292
58. Jellinger KA (2009) Recent advances in our understanding of neurodegeneration. J Neural Transm 116:1111-1162
59. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53 (Suppl 3):S26-S36
60. Johnsen D, Murphy SJ (2011) Isoflurane preconditioning protects astrocytes from oxygen and glucose deprivation independent of innate cell sex. J Neurosurg Anesthesiol 23:335-340
61. Kaushik S, Cuervo AM (2009) Methods to monitor chaperone-mediated autophagy. Methods Enzymol 452:297-324
62. Keller JN, Hanni KB, Markesbery WR (2000) Impaired proteasome function in Alzheimer's disease. J Neurochem 75:436-439
63. Klionsky DJ, Cuervo AM, Seglen PO (2007) Methods for monitoring autophagy from yeast to human. Autophagy 3:181-206
64. Koles L, Leichsenring A, Rubini P, Illes P (2011) P2 receptor signaling in neurons and glial cells of the central nervous system. Adv Pharmacol 61:441-493
65. Komori T (1999) Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease. Brain Pathol 9:663-679
66. Koren J 3rd, Jinwal UK, Lee DC, Jones JR, Shults CL, Johnson AG, Anderson LJ, Dickey CA (2009) Chaperone signalling complexes in Alzheimer's disease. J Cell Mol Med 13:619-630
67. Leak RK, Liou AK, Zigmond MJ (2006) Effect of sublethal 6-hydroxydopamine on the response to subsequent oxidative stress in dopaminergic cells: evidence for preconditioning. J Neurochem 99:1151-1163
68. Leak RK, Zigmond MJ, Liou AK (2008) Adaptation to chronic MG132 reduces oxidative toxicity by a CuZnSOD-dependent mechanism. J Neurochem 106:860-874
69. Leak RK, Castro SL, Jaumotte JD, Smith AD, Zigmond MJ (2010) Assaying multiple biochemical variables from the same tissue sample. J Neurosci Methods 191:234-238
70. Lecker SH, Goldberg AL, Mitch WE (2006) Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 17:1807-1819
71. Lee CS, Han ES, Park ES, Bang H (2005) Inhibition of MG132-induced mitochondrial dysfunction and cell death in PC12 cells by 3- morpholinosydnonimine. Brain Res 1036:18-26
72. Little AR, O'Callagha JP (2001) Astrogliosis in the adult and developing CNS: is there a role for proinflammatory cytokines? Neurotoxicology 22:607-618
73. Lloret A, Badia MC, Mora NJ, Pallardo FV, Alonso MD, Vina J (2009) Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis 17:143-149
74. Lovatt D, Xu Q, Liu W, Takano T, Smith NA, Schnermann J, Tieu K, Nedergaard M (2012) Neuronal adenosine release, and not astrocytic ATP release, mediates feedback inhibition of excitatory activity. Proc Natl Acad Sci USA 109:6265-6270
75. Manning-Bog AB, Langston JW (2007) Model fusion, the next phase in developing animal models for Parkinson's disease. Neurotox Res 11:219-240
76. Maragakis NJ, Rothstein JD (2006) Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2:679-689
77. Martin HL, Teismann P (2009) Glutathione - a review on its role and significance in Parkinson's disease. FASEB J 23:3263-3272
78. Mattson MP (2008) Hormesis defined. Ageing Res Rev 7:1-7
79. McNaught KS (2004) Proteolytic dysfunction in neurodegenerative disorders. Int Rev Neurobiol 62:95-119
80. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW (2003) Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 179:38-46
81. Menzies FM, Ravikumar B, Rubinsztein DC (2006) Protective roles for induction of autophagy in multiple proteinopathies. Autophagy 2:224-225
82. Middeldorp J, Hol EM (2011) GFAP in health and disease. Prog Neurobiol 93:421-443
83. Miller FD, Gauthier AS (2007) Timing is everything: making neurons versus glia in the developing cortex. Neuron 54:357-369
84. Moncayo J, Freitas GR de, Bogousslavsky J, Altieri M, Melle G van (2000) Do transient ischemic attacks have a neuroprotective effect? Neurology 54:2089-2094
85. Morimoto RI (2008) Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev 22:1427-1438
86. Nagai Y, Fujikake N, Popiel HA, Wada K (2010) Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases. Curr Pharm Biotechnol 11:188-197
87. 2-induced cytotoxicity involves activation of the PI3K-Akt signaling pathway. Cell Mol Biol (Noisy-le-grand) 56 (Suppl):OL1447-OL1452
88. O'Callaghan JP, Sriram K (2005) Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin Drug Saf 4:433-442
89. Ottoboni MA (1997) The dose makes the poison. Wiley, New York
90. Park WH, Kim SH (2012) MG132, a proteasome inhibitor, induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion. Oncol Rep 27:1284-1291
91. Parpura V, Heneka MT, Montana V, Oliet SH, Schousboe A, Haydon PG, Stout RF Jr, Spray DC, Reichenbach A, Pannicke T, Pekny M, Pekna M, Zorec R, Verkhratsky A (2012) Glial cells in (patho)physiology. J Neurochem 121:4-27
92. Pickart CM (2004) Back to the future with ubiquitin. Cell 116:181-190
93. Pocernich CB, Butterfield DA (2011) Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta 1822:625-630
94. Pompella A, Visvikis A, Paolicchi A, De Tata V, Casini AF (2003) The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol 66:1499-1503
95. Rajapakse N, Kis B, Horiguchi T, Snipes J, Busija D (2003) Diazoxide pretreatment induces delayed preconditioning in astrocytes against oxygen glucose deprivation and hydrogen peroxide-induced toxicity. J Neurosci Res 73:206-214
96. Rothermundt M, Peters M, Prehn JH, Arolt V (2003) S100B in brain damage and neurodegeneration. Microsc Res Tech 60:614-632
97. Schaller BJ (2007) Influence of age on stroke and preconditioning-induced ischemic tolerance in the brain. Exp Neurol 205:9-19
98. Schipper HM (2000) Heme oxygenase-1: role in brain aging and neurodegeneration. Exp Gerontol 35:821-830
99. Schipper HM, Cisse S, Stopa EG (1995) Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann Neurol 37:758-768
100. Schipper HM, Liberman A, Stopa EG (1998) Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Exp Neurol 150:60-68
101. Schipper HM, Bennett DA, Liberman A, Bienias JL, Schneider JA, Kelly J, Arvanitakis Z (2006) Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol Aging 27:252-261
102. Schipper HM, Song W, Zukor H, Hascalovici JR, Zeligman D (2009) Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. J Neurochem 110:469-485
103. Sen E, Basu A, Willing LB, Uliasz TF, Myrkalo JL, Vannucci SJ, Hewett SJ, Levison SW (2011) Pre-conditioning induces the precocious differentiation of neonatal astrocytes to enhance their neuroprotective properties. ASN Neurol 3:e00062
104. Sen J, Belli A (2007) S100B in neuropathologic states: the CRP of the brain? J Neurosci Res 85:1373-1380
105. Shao Y, McCarthy KD (1994) Plasticity of astrocytes. Glia 11:147-155
106. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348-355
107. Silver JT, Noble EG (2012) Regulation of survival gene hsp70. Cell Stress Chaperones 17:1-9
108. Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142:128-130
109. Sotrel A, Paskevich PA, Kiely DK, Bird ED, Williams RS, Myers RH (1991) Morphometric analysis of the prefrontal cortex in Huntington's disease. Neurology 41:1117-1123
110. Steele ML, Robinson SR (2012) Reactive astrocytes give neurons less support: implications for Alzheimer's disease. Neurobiol Aging 33:e421-e413
111. Steiner J, Bogerts B, Schroeter ML, Bernstein HG (2011) S100B protein in neurodegenerative disorders. Clin Chem Lab Med 49:409-424
112. Sulzer D (2007) Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 30:244-250
113. Unnithan AS, Choi HJ, Titler AM, Posimo JM, Leak RK (2012) Rescue from a two hit, high-throughput model of neurodegeneration with N-acetyl cysteine. Neurochem Int 61:356-368
114. Uversky VN (2009) Intrinsic disorder in proteins associated with neurodegenerative diseases. Front Biosci 14:5188-5238
115. Vega C, Sachleben LJ R, Gozal D, Gozal E (2006) Differential metabolic adaptation to acute and long-term hypoxia in rat primary cortical astrocytes. J Neurochem 97:872-883
116. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H (2000) NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol 99:14-20
117. Walker LC, LeVine H (2000) The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly. Mol Neurobiol 21:83-95
118. Walker LC, Levine H 3rd, Mattson MP, Jucker M (2006) Inducible proteopathies. Trends Neurosci 29:438-443
119. Weidong L, Shen C, Jankovic J (2009) Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist 15:28-35
120. Weih M, Kallenberg K, Bergk A, Dirnagl U, Harms L, Wernecke KD, Einhaupl KM (1999) Attenuated stroke severity after prodromal TIA: a role for ischemic tolerance in the brain? Stroke 30:1851-1854
121. Wilson JX (1997) Antioxidant defense of the brain: a role for astrocytes. Can J Physiol Pharmacol 75:1149-1163
122. Witt SN (2010) Hsp70 molecular chaperones and Parkinson's disease. Biopolymers 93:218-228
123. Wojtovich AP, Nadtochiy SM, Brookes PS, Nehrke K (2012) Ischemic preconditioning: the role of mitochondria and aging. Exp Gerontol 47:1-7
124. Wong E, Cuervo AM (2010) Integration of clearance mechanisms: the proteasome and autophagy. Cold Spring Harb Perspect Biol 2:a006734
125. Wu ML, Ho YC, Yet SF (2011) A central role of heme oxygenase-1 in cardiovascular protection. Antioxid Redox Signal 15:1835-1846
126. Wu YT, Tan HL, Shui G, Bauvy C, Huang Q, Wenk MR, Ong CN, Codogno P, Shen HM (2010) Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem 285:10850-10861
127. Xilouri M, Stefanis L (2010) Autophagy in the central nervous system: implications for neurodegenerative disorders. CNS Neurol Disord Drug Targets 9:701-719
128. Yang L, Fan M, Du F, Gong Q, Bi ZG, Zhu ZJ, Zhu LL, Ke Y (2012) Hypoxic preconditioning increases iron transport rate in astrocytes. Biochim Biophys Acta 1822:500-508
129. Yang W, Strong MJ (2012) Widespread neuronal and glial hyperphosphorylated tau deposition in ALS with cognitive impairment. Amyotroph Lateral Scler Other Motor NeuronDisord 13:178-193
130. Yang W, Sopper MM, Leystra-Lantz C, Strong MJ (2003) Microtubule- associated tau protein positive neuronal and glial inclusions in ALS. Neurology 61:1766-1773
131. Yang W, Ang LC, Strong MJ (2005) Tau protein aggregation in the frontal and entorhinal cortices as a function of aging. Brain Res Dev Brain Res 156:127-138
132. Yokota O, Tsuchiya K, Oda T, Ishihara T, de Silva R, Lees AJ, Arai T, Uchihara T, Ishizu H, Kuroda S, Akiyama H (2006) Amyotrophic lateral sclerosis with dementia: an autopsy case showing many Bunina bodies, tau-positive neuronal and astrocytic plaque-like pathologies, and pallido-nigral degeneration. Acta Neuropathol 112:633-645
133. Zeevalk GD, Razmpour R, Bernard LP (2008) Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother 62:236-249
134. Zhu X, Lee HG, Perry G, Smith MA (2007) Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta 1772:494-502